Biological Therapy Doublets: Pairing Rituximab with Interferon, Lenalidomide, and Other Biological Agents in Patients with Follicular Lymphoma
- 292 Downloads
Rituximab (R) is a monoclonal antibody with high therapeutic efficacy in low-grade CD20+ lymphoma. The combination of R with chemotherapy is the most common treatment option for patients with follicular lymphoma (FL). The efficacy of R has also been shown to be augmented, when used in combinations with biologicals such as interferon-alpha-2a (IFN), bortezomib, or lenalidomide. The best combination of these drugs are not well defined and a better understanding of pharmacokinetics and timing of drugs relative to the rituximab infusion is crucial. Other new targeted agents, such as inhibitors of BTK and PI3Kdelta, have also been promising in FL. Translational research questions should be added to clinical trial protocols to increase the knowledge on how the tumor microenvironment and the host immune system affect the response to the different drugs and combinations with the aim of a more individualized therapy.
KeywordsFollicular lymphoma Biological therapy Rituximab Interferon Lenalidomide Bortezomib Tumor immunoenvironment
No potential conflicts of interest relevant to this article were reported.
Papers of particular interests, published recently, have been highlighted as: • Of importance•• Of major importance
- 4.Hiddemann W, Kneba M, Dreyling M, et al. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone ─ results of a prospective randomised study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2005;106:3725–32.PubMedCrossRefGoogle Scholar
- 5.•• Salles G, Seymour J-F, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42–51. Salles et al 2011. This large randomized trial shows a significant benefit of 2 years of rituximab maintenance after first-line treatment in patients with follicular lymphoma receiving a rituximab plus chemotherapy induction regimen.PubMedCrossRefGoogle Scholar
- 6.Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustin plus Riutximab is superior in respect of progression free survival and CR rate when compared to CHOP plus Rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the STIL. Abstracts of the 2009 Annual Meeting of the American Society of Hematology Dec 5, 2009 New Orleans, Louisiana. Abstract 405.Google Scholar
- 7.Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustin plus Riutximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. Abstracts of the 2012 Annual Meeting of the American Society of Clinical Oncology; June 1–5, 2012; Chicago. Illinois. Abstract 3.Google Scholar
- 8.van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295–301.PubMedCrossRefGoogle Scholar
- 10.A phase 3 open‐label randomized study to compare the efficacy and safety of Rituximab plus lenalidomide (CC‐5013) versus Rituximab plus chemotherapy followed by Rituximab in subjects with previously untreated follicular lymphoma. The “RELEVANCE” trial (Rituximab Lenalidomide Versus Any Chemotherapy). Sponsor: Celgene Corporation Collaborator: the lymphoma academic research organisation. ClinicalTrials.gov Identifier: NCT01476787.
- 17.•• Hilchey SP, Hyrien O, Mosmann TR, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab. Blood. 2009;113(16):3809–12. The response against the immunoglobulin expressed by the follicular lymphoma cells before and after rituximab monotherapy showed an increase in FL idiotype-specific T cells providing "proof of principle" for the ability of passive immunotherapy with rituximab to elicit an active FL-specific cellular response (vaccinal effect). PubMedCrossRefGoogle Scholar
- 22.•• Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010;28(29):4480–4. Of considerable interest. In total 45 % of previously untreated patients responding to rituximab single induction (four weekly infusions) and receiving prolonged treatment (four additional doses of rituximab at 2-month intervals) were eventfree at 8 years. PubMedCrossRefGoogle Scholar
- 23.Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppä S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res. 2007;13(19):5784–921. 1.PubMedCrossRefGoogle Scholar
- 25.•• Wahlin BE, Sundström C, Holte H, et al. T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab. Clin Cancer Res. 2011;17:4136–44. The therapeutic effects of rituximab were augmented by T cells in the microenvironment (lymphnodes) and in blood. Both CD4(+) and CD8(+) cells were favorable in patients treated with rituximab and with addition of IFN-α2a the negative impact of few CD8(+) cells was abrogated. PubMedCrossRefGoogle Scholar
- 26.Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15:1110–7.PubMedGoogle Scholar
- 31.Kimby E, Jurlander J, Geisler C, Nordic Lymphoma Group, et al. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma. 2008;49:102–12.PubMedCrossRefGoogle Scholar
- 32.Kimby E, Östenstad B, de Nully Brown P, et al. Rituximab (R) in combination with interferon-α2a (IFN) shows better response than single R in patients with follicular or other CD20+ low-grade (indolent) lymphoma. A randomized phase III study from the Nordic Lymphoma Group. Ann Oncol. ICML Lugano 2011; abstract #.Google Scholar
- 34.Rossi JD, et al. Blood. 2011; ASH abstract 98:607A.Google Scholar
- 38.• Coiffier B, Osmanov EA, Hong X, et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol. 2011;12:773–84. This is the largest randomized trial on relapsed refractory follicular lymphoma and with the main end-point, PFS, statistically significant, however, not clinically important as median PFS was extended only from 11.0 to 12.8 months. PubMedCrossRefGoogle Scholar
- 41.•• Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009;114(21):4713–20. A significant reduction in formation of the F-actin immune synapse was seen in tumor-infiltrating T cells from lymphoma patients compared with age-matched healthy donor cells. A repair of this defect was noted after treatment of both FL cells and T cells with the immunomodulatory drug lenalidomide. PubMedCrossRefGoogle Scholar
- 46.Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012 Jun 1. E-pub.Google Scholar
- 47.Fowler N, Hagemeister F, McLaughlin P, et al. High response rates with lenalidomide plus rituximab for untreated indolent B cell non-Hodgkins Lymphoma. Ann Oncol ICML. 2011; Lugano abstract #137.Google Scholar
- 48.Leonard J, Jung S, Johnson JL, et al. CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. Abstracts of the 2012 Annual Meeting of the American Society of Clinical Oncology; June 1–5, 2012; Chicago, Illinois. Abstract 8000.Google Scholar
- 49.Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy. A randomized, open‐label, multicenter phase II trial. Swiss Group for Clinical Cancer Research (SAKK) in collaboration with the Nordic lymphoma group (NLG). ClinicalTrials.gov Identifier: NCT01307605.
- 50.Kahl B, Byrd J, Flinn I, et al. Significant clinical activity of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3 kinase P110D, in patients with relapsed or refractory indolent and mantle cell lymphoma. Ann Oncol. 2011 Suppl 4 ICML; Lugano, abstract #350.Google Scholar
- 51.Sven de Vos, Marshall T. Schreeder, Ian W. Flinn, Steven E. Coutre, John P Leonard. A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta Inhibitor, GS-1101 (CAL-101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (iNHL). Abstracts of the 2011 Annual Meeting of the American Society of Hematology, San Diego, California #2699Google Scholar
- 52.Winer ES, Ingham RR, Castillo JJ. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012;21(3):355–61.Google Scholar